Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 54% ± 13% | |
lung | 18 studies | 58% ± 13% | |
intestine | 13 studies | 44% ± 18% | |
brain | 11 studies | 34% ± 11% | |
kidney | 9 studies | 52% ± 17% | |
eye | 9 studies | 40% ± 17% | |
liver | 7 studies | 52% ± 23% | |
bone marrow | 6 studies | 43% ± 18% | |
lymph node | 6 studies | 57% ± 18% | |
pancreas | 5 studies | 61% ± 17% | |
uterus | 5 studies | 60% ± 19% | |
placenta | 4 studies | 70% ± 19% | |
prostate | 4 studies | 45% ± 14% | |
breast | 4 studies | 58% ± 3% | |
heart | 3 studies | 34% ± 12% | |
adrenal gland | 3 studies | 57% ± 7% | |
esophagus | 3 studies | 58% ± 23% | |
skin | 3 studies | 43% ± 10% | |
thymus | 3 studies | 66% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7313.69 | 1445 / 1445 | 100% | 290.37 | 183 / 183 |
ovary | 100% | 5603.49 | 180 / 180 | 100% | 287.32 | 430 / 430 |
stomach | 100% | 5249.65 | 359 / 359 | 100% | 485.89 | 286 / 286 |
uterus | 100% | 6399.60 | 170 / 170 | 100% | 461.96 | 459 / 459 |
lung | 100% | 7865.28 | 578 / 578 | 100% | 356.58 | 1154 / 1155 |
skin | 100% | 7268.06 | 1808 / 1809 | 100% | 390.26 | 471 / 472 |
liver | 100% | 5019.11 | 225 / 226 | 100% | 267.15 | 406 / 406 |
kidney | 100% | 6465.38 | 89 / 89 | 100% | 207.03 | 897 / 901 |
intestine | 100% | 7130.79 | 966 / 966 | 99% | 530.54 | 524 / 527 |
thymus | 100% | 5813.88 | 652 / 653 | 100% | 252.58 | 602 / 605 |
breast | 100% | 8518.64 | 459 / 459 | 99% | 338.15 | 1110 / 1118 |
bladder | 100% | 7306.00 | 21 / 21 | 99% | 464.30 | 500 / 504 |
brain | 99% | 4362.74 | 2617 / 2642 | 100% | 286.02 | 705 / 705 |
pancreas | 99% | 3318.81 | 325 / 328 | 99% | 285.78 | 177 / 178 |
prostate | 100% | 5446.39 | 244 / 245 | 99% | 253.83 | 496 / 502 |
adrenal gland | 100% | 8210.72 | 258 / 258 | 97% | 253.06 | 224 / 230 |
adipose | 100% | 9415.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 530.05 | 29 / 29 |
muscle | 100% | 18200.66 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7248.26 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 391.92 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 168.95 | 1 / 1 |
blood vessel | 100% | 7850.06 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 6426.79 | 848 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 6443.96 | 913 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 170.45 | 75 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000502 | Cellular component | proteasome complex |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005839 | Cellular component | proteasome core complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0098794 | Cellular component | postsynapse |
GO_0019773 | Cellular component | proteasome core complex, alpha-subunit complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PSMA7 |
Protein name | Proteasome subunit alpha type-7 (Proteasome subunit RC6-1) (Proteasome subunit XAPC7) Proteasome subunit alpha type Proteasome 20S subunit alpha 7 |
Synonyms | HSPC |
Description | FUNCTION: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Inhibits the transactivation function of HIF-1A under both normoxic and hypoxia-mimicking conditions. The interaction with EMAP2 increases the proteasome-mediated HIF-1A degradation under the hypoxic conditions. Plays a role in hepatitis C virus internal ribosome entry site-mediated translation. Mediates nuclear translocation of the androgen receptor (AR) and thereby enhances androgen-mediated transactivation. Promotes MAVS degradation and thereby negatively regulates MAVS-mediated innate immune response. . |
Accessions | H0Y586 ENST00000370858.3 [O14818-4] ENST00000370873.9 [O14818-1] ENST00000370861.1 [O14818-2] Q05DH1 O14818 ENST00000442551.5 |